• Bayer’s new haemophilia A drug obtains FDA approval pharmaceutical-technology
    September 03, 2018
    Bayer has received approval from the US Food and Drug Administration (FDA) for its new haemophilia A drug Jivi (BAY94-9027) as routine prophylactic therapy in previously treated adults and adolescents aged 12 years and above.
PharmaSources Customer Service